Pre-earnings brief
Reports
Wed, Oct 28, 2026
Est. EPS
—
Est. revenue
—
Implied move
±13.4%
EPS beat rate
25%
Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is significant in the healthcare sector, especially as demand for effective treatments continues to grow.
Last quarter
In Q2 2026, Viking reported an EPS of -$1.10, which was better than the expected -$1.21, resulting in a 9.09% surprise. However, the stock fell by 1.27% the following day, indicating mixed investor sentiment.
EPS beat streak
1Q
EPS beat rate
25%
Avg EPS surprise
-21.04%
Avg 1-day reaction
-0.48%
Overall, expectations for Viking Therapeutics are cautious as the company has missed EPS estimates in the past few quarters. Investors will be closely watching for any signs of improvement in financial performance.
Bull case
If Viking shows a significant reduction in losses or even a surprise profit, it could boost investor confidence and drive the stock price higher.
Bear case
Continued losses or disappointing updates on clinical trials could lead to further declines in the stock price, especially given the recent history of misses.
The print will turn on these.
Q1
What is the current status of Viking's clinical trials and their expected timelines?
Investors will be looking for clarity on trial progress as it directly impacts the company's future revenue potential and market position.
Q2
How is Viking managing its expenses to improve EPS moving forward?
Given the recent history of losses, any insights into cost management will be critical for investor confidence.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±10.3%
Why consensus could be wrong
The Street may be underestimating Viking's potential for cost management and clinical trial success, which could lead to better-than-expected EPS results.
Supporting evidence
Options are pricing a 13.4% move, suggesting higher volatility than the stock has historically shown.
Viking's recent trial updates indicate progress that could translate into revenue sooner than expected.
Key risk
If Viking's EPS comes in below -$1.00, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around Viking's ability to manage costs while advancing its clinical programs.
Bull confirmed if
A reduction in EPS losses to below -$1.00 would indicate improved financial health and operational efficiency.
Bear confirmed if
If EPS remains above -$1.10, it could confirm ongoing financial struggles.
What the market is pricing for the move.
Implied Move
±13.4%
Historical Avg
±2.7%
The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±13.4% while VKTX has averaged ±2.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
108.4%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.2%, with a raw directional average of -0.6% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
60.60%
of float
Insider
2.84%
of float
Holders
572
institutions
Top Holders· as of Jun 2026
FMR, LLC
6,335,756 sh · $180.8M
5.03%
5.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Viking beats expectations and raises guidance, history suggests the stock could rise by around 1.96% on the first day.
In line / cautious
If results are in line but management is cautious, the stock may see little movement as investors digest the information.
Miss
If Viking misses expectations again, history suggests a potential drop of around 0.01%, which could further dampen investor sentiment.
The lines on the call that would change the story.
Blackrock Inc.
6,189,649 sh · $176.7M
4.91%
-10.0%
State Street Corporation
5,606,394 sh · $160.0M
4.45%
27.6%
Vanguard Capital Management LLC
5,053,663 sh · $144.2M
4.01%
0.8%
Vanguard Portfolio Management LLC
4,484,263 sh · $128.0M
3.56%
0.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.